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. As a result, manufacturers have developed replacement chemicals to remove BPA from consumer products. However, most replacements have only slightly altered structures, retaining the bisphenol backbone and therefore the properties of BPA, including toxicity. BPA analogues were not effectively tested for safety, and human exposure is now widespread as consumers have sought products labelled BPA free under the assumption that they are safer than BPA-containing products 2 . A recent study 3 has identified BPA replacements as contaminants in scientific research. Horan and co-workers were studying the effects of exposure to endocrine-disrupting chemicals and found chromosomal abnormali ties in control mouse oocytes (that is, mice not experimentally exposed to endocrine-disrupting chemicals) at levels similar to those found in groups from previous studies that were treated with BPA. Further analy sis identified that both BPA and the BPA analogue bisphenol S (BPS) were leaching from polysulfone mouse cages. BPS is not a constituent monomer of polysulfone, but is produced during environmental degradation of the polymer. BPS, as well as bisphenols F and AF (BPF and BPAF, respectively), were confirmed as germline toxicants in further dosing studies 3 . outcomes in female mice that persisted into the third generation of offspring, who were not directly exposed to BPA 4 . The presence of bisphenol contaminants in the research laboratory is especially troublesome for scientific studies on endocrine and reproductive end points. The contamination reported by Horan and colleagues was not uniform across all animals. Only the damaged cages leached BPS and BPA, resulting in some normal controls and some with meiotic effects. If the data had only been reviewed in aggregate as a mean and standard error, the contamination might not have been discovered. If this had occurred in a study on the effects of BPA, unnoticed contaminated controls would have led to the conclusion that BPA had no effect, when in fact there was no true control with which to draw any conclusions. This scenario might be one explanation for the difficultly of reproducing results in the BPA literature and in endocrine-disruption studies in general.
The ubiquity of bisphenol contamination might be worrisome for the Consortium Linking Academic and Regulatory Insights on BPA Toxicity (CLARITY-BPA) study, a collaboration between government and academic researchers that was designed to surmount the divide in study methods and reproducibility that has led to a regulatory standstill on BPA. Animals in the CLARITY-BPA study were housed and dosed at the FDA's National Center for Toxicological Research (NCTR). A portion of the animals stayed in the government Tracking the long-term effects of exposure to bisphenols in humans is nearly impossible owing to the ubiquity of these chemicals. Bisphenols are not persistent in the body and are metabolized and excreted within hours to days, a fact that has been used to argue that BPA is safe 1 . However, Horan and colleagues demonstrate that the meiotic effects due to contamination persisted for multiple generations in the males after the contamination was eliminated. Our laboratory has also demonstrated effects from BPA on reproductive facilities for analysis and others were sent to academic grantees. In preliminary studies performed at the NCTR, the naive and vehicle control animals were reported to have serum levels of BPA that were similar to that in the mice exposed to the lowest dose in the study 5 . The source of contamination was not confirmed, and the grantee study was probably performed without the contaminant being eliminated. Additionally, neither the preliminary study nor the official CLARITY study were monitored for bisphenols other than BPA. The difficult, months-long process of removing bisphenol contamination reported by Horan and colleagues combined with the reported preliminary CLARITY study contamination calls into question the rigor of some of the controls in the CLARITY study. For example, Horan and co-workers identified effects from BPA, BPS, BPF and BPAF in the male germline, but analysis of sensitive testicular end points from CLARITY found no effect at a similar dose 6 . This discrepancy could be due to a number of different factors, including the animal model used or contamination, but it serves to highlight the point that negative results should not be considered proof of no effect under conditions in which reproducibility is challenging.
In its 2018 draft report 7 on the government branch of the CLARITY study, the FDA compares rates of female mammary gland lesions in the group receiving the lowest dose of BPA with rates in historical control animals from the NCTR. Given the ubiquity of BPA and replacement bisphenols, it is problematic to compare the CLARITY results to historical controls that might not have been examined for BPA exposure and might even date back to the days before polycarbonate cages and water bottles were known to leach BPA. We suspect that historical control mammary gland lesion rates are more indicative of low dose exposure than no exposure.
The study by Horan and colleagues reinforces the necessity of testing all replacement chemicals for the toxic properties of the original compounds. Methods to develop useful chemicals that are also safe for the endocrine system exist, but have not been effectively utilized 8, 9 . Manufacturers need to look to green and sustainable chemistry methods to avoid regret- 
N e w s & V i e w s
During the last 40 years the incidence of obesity has reached pandemic status across the developed and developing world 1 . This status is a global, major public health concern, as obesity is associated with increases in mortality of many causes, and often coexists with several health complications such as type 2 diabetes mellitus, various cancers and cardiovascular diseases 2 . The need for safe and effective weight management solutions is therefore urgent. Principle components of obesity management are that we make adjustments to our eating behaviour and increase our daily activity such that we can attain a negative energy balance to enable weight loss 3 . However, these lifestyle changes can be extremely difficult for individuals to follow, especially if we consider that eating behaviour and daily activity are shaped by lifelong learning. Thus, behaviour change requires persistent exertion from the individual.
We have been seeking to produce effective drugs for weight management to assist with behaviour modification since the late 1950s, and lorcaserin, although not new (several weight-loss clinical trials using lorcaserin have been published since 2010), is the newest in a long line of serotonergic drugs for weight management. Other serotonergic drugs (such as sibutramine and fenfluramine), which have an affinity for the 5-HT 2A or 5-HT 2B receptor subtypes, have all previously been withdrawn following concerns over their psychological and cardiovascular adverse effects 4 . Unlike other serotonergic drugs, lorcaserin is selective for the 5-HT 2C receptor subtype, which is proposed to underscore its effects on eating behaviour (reduced hunger via action on pro-opiomelanocortin (POMC) neurons) and safety. Previous studies and meta-analyses have suggested that lorcaserin is generally well tolerated and improves the likelihood of Pharmacotherapy for obesity , as an adjunct to targeted behavioural modifications, can facilitate weight loss. Previous serotonergic candidates have been withdrawn owing to undesirable cardiovascular effects. A new study in a large sample of high-risk patients shows lorcaserin treatment leads to no greater increase in cardiovascular problems than placebo -what does this result mean for personalized pharmacotherapy for obesity?
